Eagle Wealth Strategies LLC Invests $541,000 in Boston Scientific Co. (NYSE:BSX)

Eagle Wealth Strategies LLC acquired a new position in shares of Boston Scientific Co. (NYSE:BSX) in the fourth quarter, HoldingsChannel.com reports. The firm acquired 9,357 shares of the medical equipment provider’s stock, valued at approximately $541,000.

Other large investors also recently modified their holdings of the company. Bruce G. Allen Investments LLC acquired a new position in shares of Boston Scientific during the 4th quarter worth about $28,000. Venturi Wealth Management LLC lifted its stake in Boston Scientific by 58.0% in the 4th quarter. Venturi Wealth Management LLC now owns 586 shares of the medical equipment provider’s stock valued at $34,000 after purchasing an additional 215 shares during the last quarter. Motco lifted its stake in Boston Scientific by 136.3% in the 3rd quarter. Motco now owns 645 shares of the medical equipment provider’s stock valued at $34,000 after purchasing an additional 372 shares during the last quarter. Cetera Trust Company N.A acquired a new stake in Boston Scientific in the 4th quarter valued at about $43,000. Finally, Asset Dedication LLC lifted its stake in Boston Scientific by 42.6% in the 3rd quarter. Asset Dedication LLC now owns 786 shares of the medical equipment provider’s stock valued at $41,000 after purchasing an additional 235 shares during the last quarter. 89.07% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

BSX has been the subject of several recent analyst reports. TD Cowen raised their target price on shares of Boston Scientific from $65.00 to $77.00 and gave the company an “outperform” rating in a research note on Thursday, March 7th. Citigroup raised their target price on shares of Boston Scientific from $79.00 to $85.00 and gave the company a “buy” rating in a research note on Thursday. Raymond James raised their target price on shares of Boston Scientific from $73.00 to $85.00 and gave the company a “strong-buy” rating in a research note on Thursday. Royal Bank of Canada raised their target price on shares of Boston Scientific from $78.00 to $82.00 and gave the company an “outperform” rating in a research note on Thursday. Finally, Needham & Company LLC increased their price target on shares of Boston Scientific from $71.00 to $82.00 and gave the company a “buy” rating in a report on Wednesday, April 24th. Three analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $75.09.

Boston Scientific Stock Performance

Shares of NYSE:BSX opened at $73.17 on Monday. The company’s 50 day simple moving average is $67.82 and its 200 day simple moving average is $60.63. The stock has a market capitalization of $107.35 billion, a price-to-earnings ratio of 61.49, a price-to-earnings-growth ratio of 2.52 and a beta of 0.78. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.32 and a quick ratio of 0.82. Boston Scientific Co. has a 1 year low of $48.35 and a 1 year high of $74.39.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings data on Wednesday, January 31st. The medical equipment provider reported $0.55 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.51 by $0.04. The business had revenue of $3.73 billion for the quarter, compared to analysts’ expectations of $3.59 billion. Boston Scientific had a net margin of 12.06% and a return on equity of 16.63%. During the same period last year, the firm posted $0.45 earnings per share. As a group, research analysts predict that Boston Scientific Co. will post 2.32 EPS for the current fiscal year.

Insider Activity at Boston Scientific

In related news, CFO Daniel J. Brennan sold 13,662 shares of Boston Scientific stock in a transaction that occurred on Tuesday, February 20th. The shares were sold at an average price of $65.86, for a total value of $899,779.32. Following the transaction, the chief financial officer now directly owns 271,542 shares of the company’s stock, valued at $17,883,756.12. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Boston Scientific news, CFO Daniel J. Brennan sold 13,662 shares of the firm’s stock in a transaction that occurred on Tuesday, February 20th. The shares were sold at an average price of $65.86, for a total value of $899,779.32. Following the sale, the chief financial officer now owns 271,542 shares in the company, valued at $17,883,756.12. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP John Bradley Sorenson sold 16,351 shares of the firm’s stock in a transaction that occurred on Monday, April 1st. The shares were sold at an average price of $69.30, for a total transaction of $1,133,124.30. Following the completion of the sale, the executive vice president now owns 50,638 shares in the company, valued at approximately $3,509,213.40. The disclosure for this sale can be found here. Insiders have sold 50,979 shares of company stock valued at $3,418,529 over the last three months. 0.50% of the stock is owned by insiders.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.